SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of bluebird bio, Inc. (NASDAQ: BLUE) filed a class action complaint against the company’s officers and directors for alleged violations of the Securities Exchange Act of 1934 between December 11, 2017 and November 29, 2018. bluebird bio, Inc. is a clinical-stage biotechnology company developing transformative gene therapies for genetic diseases and cancer.
View this information on the law firm's Shareholder Rights Blog: https://www.robbinsarroyo.com/bluebird-bio-inc/
bluebird bio Failed to Disclose Relevant Material Facts to Mislead Shareholders of Regulatory Approval Prospects
According to the complaint, beginning on December 11, 2017, bluebird bio touted the efficacy and future prospects of its LentiGlobin™ gene therapy. Then, on December 1, 2018, bluebird issued a press release advising investors that it had “announced new long-term data from the completed Phase 1/2 Northstar (HGB-204) study of investigational LentiGlobin™ gene therapy in patients with transfusion-dependent β-thalassemia (TDT) and from the ongoing Phase 1/2 HGB-206 study of LentiGlobin in patients with sickle cell disease (SCD).” bluebird’s reported results cast doubt on the efficacy of LentiGlobin in increasing the production of anti-sickling hemoglobin. On December 3, 2018, Seeking Alpha published an article noting that these “results were lower than initial data reported a year ago indicating a lower rate of production of anti-sickling hemoglobin.” Following the clinical studies’ results announcement, bluebird’s stock price fell $6.39, or 5.2%, to close at $116.50.
bluebird bio Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com, or via the shareholder information form on the firm’s website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.